

# 2012

Baumgart T, Klautke G, Kriesen S, Kuznetsov S, Weiss DG, Fietkau R, Hildebrandt G, Manda K. **Radiosensitizing effect of epothilone B on human epithelial cancer cells.** *Strahlenther Onkol.* 188(2):177-184 (2012). PMID:22234539

Rödel F, Frey B, Gaipf U, Keilholz L, Fournier C, Manda K, Schöllnberger H, Hildebrandt G, Rödel C. **Modulation of Inflammatory Immune Reactions by Low-dose Ionizing Radiation: Molecular Mechanisms and Clinical Application.** *Curr Med Chem.* 19(12):1741-1750 (2012). PMID:22414082

Manapov F, Klöcking S, Niyazi M, Levitskiy V, Belka C, Hildebrandt G, Fietkau R, Klautke G. **Primary tumor response to chemoradiotherapy in limited-disease small-cell lung cancer correlates with duration of brain-metastasis free survival.** *J Neurooncol.* 109(2):309-314 (2012). PMID:22610939

Little MP, Azizova TV, Bazyka D, Bouffler SD, Cardis E, Chekin S, Chumak VV, Cucinotta FA, de Vathaire F, Hall P, Harrison JD, Hildebrandt G, Ivanov V, Kashcheev VV, Klymenko SV, Kreuzer M, Laurent O, Ozasa K, Schneider T, Tapio S, Taylor AM, Tzoulaki I, Vandoolaeghe WL, Wakeford R, Zablotska LB, Zhang W, Lipshultz SE. **Systematic review and meta-analysis of circulatory disease from exposure to low-level ionizing radiation and estimates of potential population mortality risks.** *Environ Health Perspect.* 120(11):1503-1511 (2012).

Krause J, Blanck O, Duerichen R, Wurster S, Andratschke N, Rades D, Hildebrandt G, Dunst J, Schweikard A, Schlaefer A. **Retrospective Accuracy Estimation for Motion Compensated Robotic Radio-surgery of the Liver.** *Medical Physics.* 39(6):3985 (2012).

Baumgart T, Kriesen S, Hildebrandt G, Manda K. **Effect of Epothilone B on cell cycle, metabolic activity, and apoptosis induction on human epithelial cancer cells - under special attention of combined treatment with ionizing radiation.** *Cancer Invest.* 30(8):593-603 (2012). PMID:22909073

Manda K, Glasow A, Paape D, Hildebrandt G. **Effects of ionizing radiation on the immune system with special emphasis on the interaction of dendritic and T cells.** *Front Oncol.* 2:102 (2012). PMID:22937525

Tiemann N, Hildebrandt G, Manda K. **Unexpected effect of the monoclonal antibody Panitumumab on human cancer cells with different KRAS status.** *Med Oncol.* 29(3):2276-83 (2012). PMID:21842425

Schweyen R, Hey J, Fränzel W, Vordermark D, Hildebrandt G, Kuhnt T. **Radiogene Karies: Ätiologie und Möglichkeiten der Prävention. Was sollte der Strahlentherapeut wissen?** *Strahlenther Onkol.* 188:21-8 (2012).

Gottschling S, Herpel E, Eberhardt WE, Heigener DF, Fischer JR, Köhne CH, Kortsik C, Kuhnt T, Muley T, Meister M, Bischoff HG, Klein P, Moldenhauer I, Schnabel PA, Thomas M, Penzel R. **The gefitinib long-term responder (LTR)-a cancer stem-like cell story? Insights from molecular analyses of German long-term responders**

**treated in the IRESSA expanded access program (EAP).** *Lung Cancer.* 77(1):183-91 (2012). PMID:22483783

Hey J, Seidel J, Schweyen R, Paelecke-Habermann Y, Vordermark D, Gernhardt C, Kuhnt T. **The influence of parotid gland sparing on radiation damages of dental hard tissues.** *Clin Oral Investig.* 17(6):1619-25 (2012). PMID:23053706

Oertel K, Spiegel K, Schmalenberg H, Dietz A, Maschmeyer G, Kuhnt T, Sudhoff H, Wendt TG, Guntinas-Lichius O. **Phase I trial of split-dose induction docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1).** *BMC Cancer.* 12:483 (2012). PMID:23083061

Mikolasch A, Manda K, Schlüter R, Lalk M, Witt S, Seefeldt S, Hammer E, Schauer F, Jülich WD, Lindequist U. **Comparative analyses of laccase-catalyzed amination reactions for production of novel beta-lactam antibiotics.** *Biotechnol Appl Biochem.* 59(4):295-306 (2012). PMID:23586863

Rödel F, Frey B, Manda K, Hildebrandt G, Hehlhans S, Keilholz L, Seegenschmiedt MH, Gaipf US and Rödel C. **Immunomodulatory properties and molecular effects in inflammatory diseases of low-dose X-irradiation.** *Front Oncol.* 2(120):1-9 (2012). PMID:23057008

Nieder C, Andratschke NH, Geinitz H, Grosu AL. **Diagnosis-specific graded prognostic assessment score is valid in patients with brain metastases treated in routine clinical practice in two European countries.** *Med Sci Monit.* 18(7):CR450-5 (2012). PMID:22739735

Andratschke N. **Stereotactic ablative radiotherapy for inoperable stage I NSCLC.** *Lancet Oncol.* 13(8):746-8 (2012). PMID:22727221

Nieder C, Grosu AL, Spanne O, Andratschke NH, Geinitz H. **Brain metastases in patients under 50 years of age: retrospective analysis.** *Clin Exp Metastasis.* 29(8):949-56 (2012). PMID:22644728

Nieder C, Andratschke NH, Geinitz H, Grosu AL. **Use of the Graded Prognostic Assessment (GPA) score in patients with brain metastases from primary tumours not represented in the diagnosis-specific GPA studies.** *Strahlenther Onkol.* 188(8):692-5 (2012). PMID:22526229

Nieder C, Grosu AL, Marienhagen K, Andratschke NH, Geinitz H. **Non-small cell lung cancer histological subtype has prognostic impact in patients with brain metastases.** *Med Oncol.* 29(4):2664-8 (2012). PMID:22467077

Bundschuh RA, Andratschke N, Dinges J, Duma MN, Astner ST, Brügel M, Ziegler SI, Molls M, Schwaiger M, Essler M. **Respiratory gated [18F]FDG PET/CT for target volume delineation in stereotactic radiation treatment of liver metastases.** *Strahlenther Onkol.* 188(7):592-8 (2012). PMID:22441441

Duma MN, Kampfer S, Schuster T, Aswathanarayana N, Fromm LS, Molls M, Andratschke N, Geinitz H. **Do we need daily image-guided radiotherapy by**

**megavoltage computed tomography in head and neck helical tomotherapy? The actual delivered dose to the spinal cord.** *Int J Radiat Oncol Biol Phys.* 84(1):283-8 (2012). PMID:22417803

Nieder C, Andratschke N. **Adding cetuximab to stereotactic radiotherapy for non-small cell lung cancer might reduce local failure rates.** *Med Hypotheses.* 78(4):420-2 (2012). PMID:22281370

Nieder C, Pawinski A, Dalhaug A, Andratschke N. **A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer.** *Radiat Oncol.* 7:3 (2012). PMID:22236606